NAD precursors (NR, NMN): what the human evidence actually shows

NAD⁺ (nicotinamide adenine dinucleotide) is a coenzyme involved in roughly 500 enzymatic reactions, including those carried out by the sirtuins, a family of proteins that has been studied extensively in the longevity literature. NAD⁺ levels decline with age in tissue measurements; the proposed therapeutic logic is to restore them through dietary precursors.

The two most-marketed precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

What the evidence actually establishes#

That NR and NMN raise blood NAD⁺. Multiple human trials confirm this. A 2019 trial (Conze et al.) showed NR doses of 100–1,000 mg/day raised whole-blood NAD⁺ by 22–142% in healthy overweight adults over 8 weeks. Similar results have been reported with NMN at comparable doses.

That mouse studies show benefits across many ageing endpoints. Rodent work has reported improvements in metabolic, cardiovascular, neurological, and reproductive ageing markers with NAD-precursor supplementation. This is the basis for most of the longevity claims.

What the evidence doesn't establish#

That higher blood NAD⁺ produces meaningful clinical benefit in healthy adults. Most published human trials have measured surrogate markers (NAD⁺ levels, biomarkers of muscle metabolism, blood pressure, insulin sensitivity) over weeks to months. Effects on these endpoints have been modest and inconsistent.

That NR or NMN extends healthspan or lifespan in humans. There is no human evidence for this. Lifespan studies in humans are impractical and the surrogate-marker evidence is not strong enough to confidently infer it.

That the form (NR vs NMN vs other precursors) meaningfully matters in vivo. Some metabolic differences exist in animal models; whether they translate is unclear.

Specific human trial results#

A 2020 review (Mehmel et al.) summarised the main human NR trials; the NMN findings below draw on separate primary studies. Highlights:

• Insulin sensitivity in prediabetic postmenopausal women: Yoshino et al. 2021 reported NMN improved muscle insulin sensitivity in prediabetic postmenopausal women. Small trial, replication awaited.
• Cardiovascular markers: Several NR trials showed modest reductions in BP in adults with elevated baseline; effects on arterial stiffness were inconsistent.
• Skeletal muscle and physical function — small trials in older adults show modest, mixed effects on strength and gait.

The honest summary of the clinical data: NAD precursors do what they say on the tin biochemically, but the downstream clinical effects so far are subtle and the longevity claims dramatically outrun the data.

Regulatory status in the UK#

• NR is generally permitted in food supplements (approved by EFSA as a novel food in 2017 under the Niagen brand).
• NMN's status is more contested. In late 2022 the FDA reclassified NMN as not a legal dietary supplement in the US (after a drug approval application). The UK Food Standards Agency considers NMN under retained EU novel-food rules; sale is in a grey area.
• Neither is a licensed medicine. The MHRA does not regulate supplements as medicines.

Side effects and interactions#

Both compounds appear well-tolerated in trial doses. Reported issues include mild GI symptoms and skin flushing at higher doses (more pronounced with niacin / nicotinic acid than with NR/NMN).

Long-term safety data in healthy adults is limited. Caution is warranted in people with active or treated cancer; NAD-dependent pathways are involved in DNA repair, which has theoretical implications either way; the safety profile in cancer-survivor populations is not established.

The honest read#

This is a category where the cell biology is interesting and the human evidence is C-grade. Trials demonstrate that blood NAD⁺ rises; they don't demonstrate that healthy adults live longer, look better, or perform better in clinically meaningful ways.

A reasonable consumer position: if you want to spend money here, treat it as an experiment in your own body with a 3–6 month review, knowing the published clinical benefit per dollar is small. A more conservative position is to spend the same money on a gym membership and decent food, where the long-term evidence is much stronger.

We don't endorse a specific NAD precursor product. The space is full of marketing.